Comparative Pharmacology
Head-to-head clinical analysis: XYLOCAINE PRESERVATIVE FREE versus XYLOCAINE VISCOUS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: XYLOCAINE PRESERVATIVE FREE versus XYLOCAINE VISCOUS.
XYLOCAINE PRESERVATIVE FREE vs XYLOCAINE VISCOUS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lidocaine stabilizes the neuronal membrane by inhibiting sodium ion influx, thereby blocking impulse initiation and conduction. It binds to voltage-gated sodium channels in the inactivated state, preventing depolarization and propagation of action potentials.
Lidocaine is an amide-type local anesthetic that blocks voltage-gated sodium channels, inhibiting nerve impulse propagation and reducing pain sensation.
Adult dose: 1-30 mL of 1% or 2% solution (10-600 mg) via subcutaneous infiltration, peripheral nerve block, or epidural; max 4.5 mg/kg (300 mg without epinephrine, 7 mg/kg [500 mg] with epinephrine) per 2-hour period.
Adults: 5-15 mL orally (or swish and spit) 4-6 times daily, not to exceed 4 doses in 12 hours or 30 mL in 12 hours.
None Documented
None Documented
Terminal elimination half-life approximately 1.5-2 hours in adults; prolonged in hepatic impairment (up to 3-4 hours) and congestive heart failure.
Terminal elimination half-life: 1.5-2 hours in adults; prolonged in hepatic impairment or heart failure (up to 6-8 hours). In neonates, half-life may be 3-6 hours due to immature metabolism.
Renal excretion of metabolites (90-95% as metabolites, <5% unchanged); biliary/fecal excretion minimal (<1%).
Renal excretion of metabolites: ~90%. Unchanged drug: <10%. Biliary/fecal: minor.
Category C
Category C
Local Anesthetic
Local Anesthetic